Johnson & Johnson (JNJ) Stock: Rises to $273 as FDA Approves RYBREVANT FASPRO for Head and Neck Cancer
Johnson & Johnson (JNJ) Stock: Rises to $273 as FDA Approves RYBREVANT FASPRO for Head and Neck Cancer Blockonomi
Covered in this story
What has happened since
- Johnson & Johnson is up 0.0% since this was published, 2 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Johnson & Johnson
- Bernstein: $253 → $270 by Oct 2027 · Market Perform via Investing.com
- RBC Capital Markets: $249 → $280 by Oct 2027 · Outperform via GuruFocus
- RBC Capital Markets: $255 → $290 by Oct 2027 · Outperform via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $JNJ yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Johnson & Johnson →Dalsna Finance is currently tracking 38 stories mentioning Johnson & Johnson, the earliest published 28 Apr 2017.
Summary aggregated from Blockonomi's public RSS feed. The full reporting belongs to Blockonomi — please read it on their site.